Dickinson Andrew D 4
4 · GILEAD SCIENCES, INC. · Filed Sep 11, 2025
Insider Transaction Report
Form 4
Dickinson Andrew D
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2025-09-10+3,696→ 163,806 total - Tax Payment
Common Stock
2025-09-10$115.25/sh−1,751$201,803→ 162,055 total - Exercise/Conversion
Restricted Stock Unit
2025-09-10−3,696→ 31,219 total→ Common Stock (3,696 underlying)
Footnotes (2)
- [F1]Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
- [F2]The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.